Services at Banner MD Anderson Cancer Center  

Clinical Trial Listing


Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit

Open for Enrollment Clinical Trials

Breast Cancer

Colorectal Cancer



Ovarian Cancer

Pancreatic Cancer

(back to top)

 Active Clinical Trials (No longer enrolling patients)

Cancer Type Name of Study Identifier # Principal Investigator
Bladder Cancer

Celgene Mt Sinai AR-BLD PI-008 
Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

NCT01331824 Dr. Bryan Wong
Breast Cancer

Novartis (CRADY24315) 
An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer


Dr. Mary Cianfrocca
Breast Cancer

AbbVie M12-895 (Brocade) (Ph 2) 
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer


Dr. Mary Cianfrocca
Breast Cancer

MDACC 2010-0559
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer

NCT01266642 Dr. Emily Grade

BMS CA180-330 (Simplicity) 
Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

NCT01244750 Dr. Horst Klueppelberg

GSK OMB112517 (Prolong) 
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy

NCT01039376 Dr. Horst Klueppelberg
Lung Cancer

Genentech GO28754 (Birch) 

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT01846416 Dr. Tomislav Dragovich
Lung Cancer

Roche BO28984 (Alectinib vs Crizotinib) 
A Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

NCT02075840 Dr. Boris Naraev
Lymphoma Kyowa 0761-010
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma
NCT01728805 Dr. Javier Munoz
Lymphoma GSK OMB113676 (Homer)Rituximab vs Ofatumumab
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
NCT01200589 Dr. Horst Klueppelberg
Lymphoma Janssen:  A Study of PCI-32765 (Ibrutinib) in Combination with Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants with Previously Treated Indolent Non-Hodgkin Lymphoma
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
NCT01974440 Dr. Javier Munoz
Lymphoma Millennium C25003 (A+AVD vs ABVD)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
NCT01712490 Dr. Javier Munoz
Lymphoma Bayer (Copanlisib)
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (CHRONOS-1)
NCT01660451 Dr. Javier Munoz

BMS CA209-067- Nivolumab +Ipilumimab vs Placebo Met. Melanoma 
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

NCT01844505 Dr. Jade Homsi

GSK MEK116513 BRAF Inh + MEK Inh in Melanoma 
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

NCT01597908 Dr. Jade Homsi
Renal Cell A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy NCT01865747 Dr. Bryan Wong

(back to top)

Banner MD Anderson Cancer Center
Higley Road and US 60
2946 E. Banner Gateway Drive
Gilbert, AZ 85234
(480) 256-6444
(855) 256-6444

Follow Us:  
Facebook IconPinterestTwitter IconBlogYouTube Icon
Jump to top links